Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Surgery for tough lung infections: new study reveals key insights on drug resistance

NCT ID NCT07167823

Knowledge-focused Sponsor: University of Health Sciences Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at 350 patients who had surgery (decortication) to treat severe lung infections called empyema, including cases caused by tuberculosis and drug-resistant bacteria. The goal was to understand the types of germs causing these infections and how they affect recovery after surgery. Researchers found that patients with positive cultures had more complications, highlighting the challenge of multidrug resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Decortication (surgery to remove infected material and fibrous tissue from the lung lining)
What this could lead to
If successful, this study could help doctors better understand which patients benefit most from decortication and how to manage drug-resistant infections.
What could go wrong
This is a completed observational study, not a controlled trial. Results may not apply to all empyema patients, and the findings are descriptive rather than proving a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

350 people

The number who actually took part.

Started

Jan 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with pleural empyema (MDR bacterial and tuberculous) who underwent surgical decortication (VATS or open thoracotomy) and admitted in thoracic surgery unit of Services hospital Lahore.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with pleural empyema based on clinical, radiological, and microbiological confirmation. * Patients who underwent surgical decortication for complicated or refractory empyema. Exclusion Criteria: * Patients with non-infectious pleural effusions (e.g., malignant pleural effusion, hemothorax, or chylothorax). * Empyema cases resolved with medical management alone (antibiotics and/or chest tube drainage) without requiring surgical intervention. * Patients with severe systemic conditions (e.g., end-stage organ failure, terminal malignancy) where empyema management was not the primary therapeutic focus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis pleural empyema tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacterial sepsis Pleural empyema Tuberculosis (TB)

Contacts and locations

Locations

  • Services Institute of Medical Sciences (SIMS), Services Hospital, Lahore

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.